Trial 4B-21-1


A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination with Cetrelimab Versus Concurrent Chemoradiotherapy in Participants with Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Local, Chemotherapy: Systemic, Radiation: Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Siamak Daneshmand, M.D.
Other Trial Staff:  Aaron Mejia, Coordinator, Cheryl Kefauver, Coordinator, Rubina Hassan, D.M., Vicky Araujo, Coordinator, Lagrimas Ilagan, D.M., Roberto Tejada, Coordinator, Shamim Jhimlee, Coordinator, Honorina Enright, D.M., Amanda Luna, Coordinator, Ileana Aldana, Coordinator, Hilma Bolton, Coordinator, Bartolo Santos, Coordinator, Aubrianne Cho, Coordinator, Thomas Elimihele, D.M., Viviana Moreno, D.M., Sarah Chevalier, Coordinator, Heather Leatherwood, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.